Dr. Mark Frattini's Novel Anti-Cancer Therapy Licensed to Lin BioScience
Lin BioScience has licensed the intellectual property portfolio for a novel inhibitor of CDC7 kinase called LBS-007 developed by HICCC researcher Dr. Mark Frattini and his team in collaboration with Memorial Sloan-Kettering Cancer Center.
LBS-007 shows preclinical effectiveness against nearly 80 malignancies, ranging from leukemia and non-small cell lung cancer to melanoma and ovarian cancer. Its licensing is the culmination of almost a decade of work developing a unique CDC7 inhibitor that is less prone to off-target effects. ItRead the full story at http://techventures.columbia.edu/news-and-events/latest-news/lin-bioscience-licenses-novel-anti-cancer-therapy-hematological.